glp 1 agonist inflammation Frontiers The multifaceted role of GLP-1
Description
I.V., Intravenous
As I highlighted at the beginning, both Eli Lilly and Novo Nordisk have been in a drawdown over the past year
For that reason, much of the care management strategies employed when prescribing GLP-1 medications borrow from evidence-based obesity care management and diabetes care management
ESC The ESC guidelines recommend the use of GLP-1 RAs in overweight or obese patients with T2DM to promote weight reduction (Class IIa, LoE B)
This is because no specific funding had been allocated for this purpose
